Workflow
Moderna(MRNA)
icon
Search documents
2 Growth Stocks Down 25% to Buy Right Now
The Motley Fool· 2024-07-15 09:10
Discounted stock prices make these strong brands worth considering as investments. Let's take a look at two stocks that trade down significantly from recent highs and see why they might be good stocks to buy right now. Smart investors see that disparity and know it means there are some discounted stocks to be found. The trick, of course, is discerning which of the discounted stocks represent quality companies experiencing a short-term issue (or issues). Not every stock that falls is a wise investment. Howev ...
Is Moderna Stock a Buy?
The Motley Fool· 2024-07-14 10:27
Moderna (MRNA -1.11%) went from being an unknown biotech to a household name thanks to its work developing and marketing one of the most successful COVID-19 vaccines. Though the company has delivered outsize returns since late 2019, its shares are down more than 70% from their peak in 2021. Moderna's coronavirus-related revenue dropped off a cliff, dragging down its bottom line (and its stock price along with it). However, several developments may suggest that it is still worth investing in Moderna. Is the ...
3 Healthcare Stocks to Sell in July Before They Crash & Burn
Investor Place· 2024-07-08 20:45
The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated. Walgreens Boots Alliance (WBA) Walgreens has also been hit by tough competition from the large retail chains such as Walmart (NYSE:WMT) and Target (NYSE:TGT), along with increased utilization of direct mail prescription-filling services by consumers. Partly as a ...
Moderna Receives HHS Grant to Develop a Bird Flu Vaccine
Investopedia· 2024-07-02 14:41
Moderna on Tuesday announced a $176 million federal grant to develop a bird flu vaccine for humans. The biotech firm noted that the highly infectious H5 influenza virus causes severe illness in birds and poses a transmission risk to people. Moderna began a Phase 1/2 trial of a potential vaccine in 2023, and expects the results of that study this year. The company announced that the $176 million project award from the Rapid Response Partnership Vehicle (RRPV) of the U.S. Department of Health and Human Servic ...
Moderna Scores Federal Funding For mRNA Bird Flu Vaccine As Pandemic Fears Grow
Forbes· 2024-07-02 11:30
Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans . Getty Images Moderna said the U.S. government funds will bankroll "late-stage development for an mRNA-based vaccine" against H5 influenza virus to en ...
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
ZACKS· 2024-07-02 09:11
The CHMP's recommendation will now be reviewed by the European Commission (EC) and a final decision is expected shortly. If authorized, mResvia will be Moderna's second approved product in the region. The above news comes just a few days after Moderna suffered a major setback after the U.S. Centers for Disease Control and Prevention (CDC) revised their recommendation for the use of RSV vaccines for the upcoming respiratory virus season. This recommendation is based on data from data from the phase III Conqu ...
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
Investor Place· 2024-06-28 14:28
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials. Undoubtedly, most of the drug candidates will run into a wall at some point in the trials. It can be a long and grueling move from Phase I to the finish line. For the biotech firms that can advance past all clinical trials and prove that a treatment is both safe and effective, the rewards could have the po ...
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
ZACKS· 2024-06-27 16:10
An 18-month analysis of follow-up data showed that Moderna's RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with the 80.9% vaccine efficacy achieved by the vaccine at a follow-up period of 3.7 months. Image Source: Zacks Investment Research This efficacy rate was also significantly lower compared with GSK's Arexvy and Pfizer's Abrysvo, both of which are also approved for similar use by the FDA. These companies also presented data on their respective R ...
2 Stocks Down More Than 30% to Buy Right Now
The Motley Fool· 2024-06-27 08:27
The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks that have dropped in the double digits over the past few years are coronavirus vaccine giants Moderna (MRNA -11.01%) and Pfizer (PFE -2.04%). Adria Cimino (Moderna): Moderna entered the coronavirus vaccine market with a splash in early pandemic days, becoming a vaccine leader along with Pfizer. The vaccine, Moderna' ...
Why Is Moderna Stock Trading Lower On Wednesday?
Benzinga· 2024-06-26 16:54
Loading... In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms. Efficacy of a single dose of GSK Plc's GSK Arexvy over two calendar years showed vaccine efficacy of 73.3% (W/o season covariate) and 78.6% in severe infection. Last year, GSK's Arexvy and Pfizer's Abrysv ...